Myasthenia gravis symptom response to huperzine A, pyridostigmine bromide, and an immunomodulatory incorporated regimen: A multi-case study

Abstract

Myasthenia gravis (MG) is an autoimmune disease known to affect the transmission of signals at the neuromuscular junction. Despite the utilization of multiple methods to alleviate symptoms and improve the quality of life for individuals with MG, a comprehensive and entirely effective regimen has yet to be achieved. Pyridostigmine bromide and huperzine A are pharmacological agents that function as inhibitors of red blood cell-acetylcholinesterase. These compounds are extensively employed in the treatment protocols for myasthenia gravis. Nevertheless, the distinct disparities between huperzine A and Pyridostigmine bromide necessitate further investigation into the potential of these drugs in relieving the clinical symptoms of MG. The current research investigated MG symptom enhancement after four weeks of huperzine A, pyridostigmine bromide, and an immunomodulatory integrated regimen. Six MG patients were monitored for subjective enhancements in MG symptoms and quality of life as well as red blood cell-acetylcholinesterase activity and acetylcholine receptor antibody binding reduction before and four weeks after the initiation of the treatment protocol. The results showed that MG symptoms were reduced in all the monitored cases with an average overall enhancement of 80.6±5.5%. Additionally, the quality of life questionnaire revealed an overall enhancement of 72±5.7%. Additionally, the red blood cell-acetylcholinesterase activity was regulated in all patients within the pre-set therapeutic target of 25-35 U/g Hb. Although a decent reduction in acetylcholine receptor antibody binding was achieved in all patients, none of them reached normal levels for this index. The present findings on the integration of huperzine A and other immunomodulatory drugs into the therapy regimen for MG are exceedingly promising, particularly in terms of the potential reduction in dosage requirements or even the elimination of pyridostigmine bromide administration. However, it is imperative to examine different therapeutic approaches in future research endeavors.